Results 91 to 100 of about 280,160 (254)

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

Advances in cholesterol and lipoproteins detection for healthcare: A review

VIEW, EarlyView.
Cholesterol is one of the main biomarkers related to the development of cardiovascular diseases. Its detection still relies on traditional methods of analysis, such as gas and liquid chromatographies. Detection of free cholesterol in saliva with redox or enzymatic sensors or detection of lipoproteins in blood with aptamer sensors are currently the most
Jacopo Giaretta, Somayeh Fardindoost, Azadeh Abdi, Kaveh Yazdani, Longfei Yin, Syamak Farajikhah, Mina Hoorfar, Fariba Dehghani   +7 more
wiley   +1 more source

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19 [PDF]

, 2022
Olivier Deckmyn, Thierry Poynard, Pierre Bédossa, Valérie Paradis, Valentina Peta, Raluca Pais, Vlad Ratziu, Dominique Thabut, Angélique Brzustowski, Jean–François Gautier, P. Cacoub, Dominique Valla   +11 more
openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Isotope-coded protein label based quantitative proteomic analysis reveals significant up-regulation of apolipoprotein A1 and ovotransferrin in the myopic chick vitreous

Scientific Reports, 2017
This study used isotope-coded protein label (ICPL) quantitative proteomics and bioinformatics analysis to examine changes in vitreous protein content and associated pathways during lens-induced eye growth.
Feng-Juan Yu, T. C. Lam, Long-qian Liu, R. K. Chun, Jimmy K W Cheung, King-kit Li, C. To   +6 more
semanticscholar   +1 more source

EFFECT OF DABIGATRAN ON SERUM APOLIPOPROTEIN B AND APOLIPOPROTEIN A1 CONCENTRATIONS

Journal of the American College of Cardiology, 2013
Dabigatran is a direct thrombin inhibitor that reduces stroke risk in patients with atrial fibrillation and additional thromboembolic risk factors. Carboxylesterases, which convert dabigatran etexilate to its’ active form, dabigatran, have also been shown to influence lipid metabolism ...
Joseph, Philip, Pare, Guillaume, Connolly, Stuart, Ezekowitz, Michael, Wallentin, Lars, Reilly, Paul, Themeles, Ellison, Yusuf, Salim   +7 more
openaire   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Is Apolipoprotein A1 a Better Biomarker in Chronic Thromboembolic Pulmonary Hypertension Than High Density Lipoprotein Cholesterol? [PDF]

, 2020
Ghaleb Khirfan, M. Li, X. Wang, Gustavo A. Heresi   +3 more
openalex   +1 more source

Hormonal regulation of apolipoprotein A1

, 1994
Bibliography: p. 154-162.
openaire   +2 more sources